arrow
S

Sheena McCormack

University of London
H指数:35
被引数:6,189

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial

东非和南非以顺性别女性为主的人群中HIV暴露前预防中F/TAF与F/TDF的比较:一项随机、析因、非劣效性试验

2026-06-010
PRE
Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study

了解东非和南部非洲参与HIV疫苗试验并同期随机分配接受口服前暴露预防的试验设计与可接受性:一项纵向定性研究

2026-05-161
PRE
Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018-2022 HIV vaccine preparedness cohort in Masaka, Uganda

估计乌干达马萨卡成人艾滋病病毒发病率并评估相关危险因素:来自2018-2022年艾滋病疫苗准备队列的证据

2026-05-080
OA
Contraceptive use, prevalence and incidence of pregnancy and associated factors among women participating in a vaccine preparedness cohort study in Masaka, Uganda, a retrospective secondary analysis

在乌干达Masaka参加疫苗准备队列研究的妇女中,避孕药具的使用,患病率和妊娠发生率及相关因素,回顾性二次分析

2024-12-270
OAAI
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies
2024-03-148
OAAI
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
2023-12-0110
OAAI
Understanding experiences of potential harm among MSM (cis and trans) using HIV self-testing in the SELPHI randomised controlled trial in England and Wales: a mixed-methods study
2023-08-222
OAAI
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

SARS-CoV-2自扩增RNA疫苗的COVAC1 2a期扩大安全性和免疫原性研究

2023-02-0118
OAAI
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
2023-01-090
OAAI
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

抗新型冠状病毒肺炎自我扩增RNA疫苗的安全性和免疫原性: COVAC1,I期剂量范围试验

2022-02-0194
OAAI
Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales
2021-02-0115
OAAI
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
2020-06-2610
OAAI